site-logo
  • LiquidHALLMARK®
  • Resources
    • Publications
    • News & Events
  • Patients
  • Company
    • About Us
    • News & Events
    • Careers
    • Contact Us
  • Portal Login

News & Events

Show Filters
No Record Found
News
Lucence secures US Medicare approval for its cancer tests
20 March 2023
News
Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer
22 February 2023
News
Lucence Shares Promising Interim Data from LIQUIK Prospective Study at ISLB 2022
23 October 2022
News
amplimark-2
Lucence and Omnigen Partner to bring Amplicon-based Liquid Biopsy Tests to Turkey
18 October 2022
News
Lucence Collaborates with National Cancer Centre Singapore to Launch Prospective Liquid Biopsy Study for Prostate Cancer
26 September 2022
News
Local Study Demonstrates Synergies of Using Blood-based Liquid Biopsies to complement Tissue Biopsies for Lung Cancer Diagnosis
28 July 2022
News
Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy
14 July 2022
News
Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting
31 May 2022
  • 1
  • 2
  • 3
prev
Up arrow Back to top
Footer logo
Reach Us
3520 W Bayshore Road, Palo Alto, CA 94303 [email protected] (888) 582 3623
Subscribe for Updates

    Follow Us
    • facebook facebook-white
    • linkedin linkedin-white
    • twitter twitter-white

    © 2023 Lucence Health Inc. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners.

    LiquidHALLMARK® | AmpliMark™ | Publications| Careers | About | Privacy

    Lucence secures approval for its Singapore-invented cancer tests from Medicare

    >